To analyze the clinical effect of vascular targeted drug combined with chemotherapy in the treatment of advanced liver cancer, the clinical effect of middle and late liver cancer is the target of this investigation.50 patients treated in the oncology department of our hospital from 2021 to 2022. Groups were grouped according to different treatment modalities, and the number of cases per group was 25. The experimental group was treated with vascular targeted drugs + chemotherapy, and the control group was treated with chemotherapy. Compare the specific implementation of the two groups. Relevant indicators in the experimental group were better than those in the control group (P <0.05). After the intervention of vascular targeted drugs + chemotherapy, the safety of patients with advanced liver cancer is improved, the existence value of tumor markers is improved, the body immunity of patients is improved, and the treatment compliance of patients is improved, which is worth promoting.

Cui Chuanbao, Zhao Qi. Clinical effect of vascular targeting drugs combined with chemotherapy in advanced liver cancer. International Journal of Frontiers in Medicine (2023), Vol. 5, Issue 8: 138-142. https://doi.org/10.25236/IJFM.2023.050820.

[1] Xiong Huagang, Yang Zhigang, Zhang Liu, et al. Clinical efficacy and safety of hepatic artery embolization chemotherapy combined with small molecule targeted therapy for middle and advanced liver cancer [J]. Pharmaceutical industry, 2021 (13): 1-2.

[2] Huang Zhongwu. Clinical efficacy of molecular targeted drugs combined with hepatic artery embolization chemotherapy in hepatocellular carcinoma [J]. Chinese Science and Technology Journal Database (citation version) Medicine and Health, 2023 (4): 4-5.

[3] Li Xiaoli, Ge Xin. Clinical efficacy of molecular targeted drugs combined with hepatic artery embolization chemotherapy in hepatocellular carcinoma [J]. Chinese Science and Technology Journal Database (full-text edition) Medicine and Health, 2021 (11): 21-22.

[4] Li Xiaoli, Ge Xin. Clinical efficacy of molecular targeted drugs combined with hepatic artery embolization chemotherapy in hepatocellular carcinoma [J]. Chinese Science and Technology Journal Database (full-text edition) Medicine and Health, 2021 (11): 12-13.

[5] Yang Rongbin, Li Wei, Li Shaoming, et al. Effect of small molecule targeted therapy combined with hepatic artery embolization chemotherapy on clinical efficacy and survival time in patients with advanced liver cancer [J]. China Practical Medicine, 2022, 17 (2): 11-13.

[6] Defang F, Wei S, Shan J, et al. Clinical effects of recombinant human vascular endothelial inhibitor combined with chemotherapy for advanced gastrointestinal cancer[J]. Journal of Modern Oncology, 2015.

[7] Li Youzan, Chen Kai, Zhao Ji, et al. Clinical study of hepatic artery perfusion chemotherapy combined with immunization and targeted therapy for unresectable hepatocellular carcinoma [J]. Clinical Journal of Practical Hospital, 2022 (23): 19-21.

[8] Yan Xiangyong, Li Jun, Niu Xiaojuan, et al. Safety and clinical efficacy of PD-1 inhibitors combined with targeted drugs in advanced primary liver cancer [J]. Modern Medical Oncology, 2023, 31 (5): 6-7.

[9] Diao Yongen, Wang Yu, Luo Yunxia, Guo Jian, Zhu Ying, Yu Zhonghe. Progress in the treatment of patients with advanced liver cancer [J]. Liver Disease Journal of Integrated Traditional Chinese and Western Medicine, 2022, 32 (11): 1040-1044.